ESA APPRISE Oncology Program Enrollment Form for Healthcare Providers Current as of[removed]This document may not be part of the latest approved REMS. For the use of erythropoiesis stimulating agents (ESAs*) Aranesp® - Amgen - Document - PDFSEARCH.IO

First Page	Meta Content
	ESA APPRISE Oncology Program Enrollment Form for Healthcare Providers Current as of[removed]This document may not be part of the latest approved REMS. For the use of erythropoiesis stimulating agents (ESAs*) Aranesp® Add to Reading List Open Document File Size: 247,28 KB Share Result on Facebook City Reference / / Company Amgen Inc. / Janssen Products LP. / / Facility Based Clinic / Hospital Designee / / / IndustryTerm biologic products / healthcare / review tool / healthcare professional / healthcare providers / / MedicalCondition cervical cancers / tumor / cancer / cancer receiving hormonal agents / cancer receiving myelosuppressive chemotherapy / stroke / blood clots / fatigue / heart failure / heart attack / anemia / / MedicalTreatment red blood cell transfusions / chemotherapy / radiotherapy / counseling / / Organization US Food and Drug Administration / ESA APPRISE Oncology Program Call Center / / Person ESA APPRISE / / / Position Field Representative / / Product Aranesp / Epogen®/Procrit® Medication / / Technology chemotherapy / ESA / / URL www.esa-apprise.com / / SocialTag Biology Pharmacology Erythropoietin Darbepoetin alfa Amgen Epoetin alfa Erythropoiesis-stimulating agents Growth factors Medicine

ESA APPRISE Oncology Program Enrollment Form for Healthcare Providers Current as of[removed]This document may not be part of the latest approved REMS. For the use of erythropoiesis stimulating agents (ESAs*) Aranesp® Add to Reading List